FDA Inspection 1155648 — Amaris Clinical
The FDA completed an inspection of Amaris Clinical on October 8, 2021 in Chengalpattu. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- October 8, 2021
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Chengalpattu (India)
Additional Details
Clinical BA/BE